SG10201913303XA - Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof - Google Patents

Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof

Info

Publication number
SG10201913303XA
SG10201913303XA SG10201913303XA SG10201913303XA SG10201913303XA SG 10201913303X A SG10201913303X A SG 10201913303XA SG 10201913303X A SG10201913303X A SG 10201913303XA SG 10201913303X A SG10201913303X A SG 10201913303XA SG 10201913303X A SG10201913303X A SG 10201913303XA
Authority
SG
Singapore
Prior art keywords
antibodies
methods
activatable
activatable anti
Prior art date
Application number
SG10201913303XA
Inventor
Kimberly Ann Tipton
James William West
Chanty Mariategue Chan
Original Assignee
Cytomx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytomx Therapeutics Inc filed Critical Cytomx Therapeutics Inc
Publication of SG10201913303XA publication Critical patent/SG10201913303XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biomedical Technology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG10201913303XA 2015-07-13 2016-07-13 Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof SG10201913303XA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562191902P 2015-07-13 2015-07-13
US201562205825P 2015-08-17 2015-08-17
US201662295314P 2016-02-15 2016-02-15
US201662323543P 2016-04-15 2016-04-15
US201662333629P 2016-05-09 2016-05-09

Publications (1)

Publication Number Publication Date
SG10201913303XA true SG10201913303XA (en) 2020-03-30

Family

ID=56561467

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201913303XA SG10201913303XA (en) 2015-07-13 2016-07-13 Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof

Country Status (16)

Country Link
US (2) US10513558B2 (en)
EP (1) EP3322732A2 (en)
JP (2) JP7014706B2 (en)
KR (1) KR20180040138A (en)
CN (2) CN108368170B (en)
AU (2) AU2016294440B2 (en)
BR (1) BR112018000768A2 (en)
CA (1) CA2991976A1 (en)
EA (1) EA201890285A1 (en)
HK (1) HK1250033A1 (en)
IL (1) IL256771B2 (en)
MA (1) MA42447A (en)
MX (2) MX2018000621A (en)
SG (1) SG10201913303XA (en)
WO (1) WO2017011580A2 (en)
ZA (1) ZA201800692B (en)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2925106C (en) 2013-09-25 2023-11-14 Cytomx Therapeutics, Inc. Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
TWI680138B (en) 2014-01-23 2019-12-21 美商再生元醫藥公司 Human antibodies to pd-l1
TWI681969B (en) * 2014-01-23 2020-01-11 美商再生元醫藥公司 Human antibodies to pd-1
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody molecules to pd-1 and uses thereof
JOP20200096A1 (en) 2014-01-31 2017-06-16 Children’S Medical Center Corp Antibody molecules to tim-3 and uses thereof
WO2015116933A2 (en) 2014-01-31 2015-08-06 Cytomx Therapeutics, Inc. Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
NZ728688A (en) 2014-07-22 2023-06-30 Cb Therapeutics Inc Anti-pd-1 antibodies
CN105330740B (en) * 2014-07-30 2018-08-17 珠海市丽珠单抗生物技术有限公司 Anti- PD-1 antibody and its application
JP6909153B2 (en) 2014-08-05 2021-07-28 アポロミクス インコーポレイテッド Anti-PD-L1 antibody
WO2016040880A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of alk inhibitors
TWI595006B (en) * 2014-12-09 2017-08-11 禮納特神經系統科學公司 Anti-pd-1 antibodies and methods of use thereof
MA41374A (en) 2015-01-20 2017-11-28 Cytomx Therapeutics Inc MATRIX METALLOPROTEASE CLIVABLE AND SERINE PROTEASE CLIVABLE SUBSTRATES AND METHODS OF USE THEREOF
WO2016208696A1 (en) 2015-06-24 2016-12-29 Ｊｃｒファーマ株式会社 Fusion protein containing bdnf
WO2016208695A1 (en) * 2015-06-24 2016-12-29 Ｊｃｒファーマ株式会社 Anti-human transferrin receptor antibody permeating blood-brain barrier
WO2017031242A1 (en) 2015-08-20 2017-02-23 Sutro Biopharma, Inc. Anti-tim-3 antibodies, compositions comprising anti-tim-3 antibodies and methods of making and using anti-tim-3 antibodies
CN107949573B (en) 2015-09-01 2022-05-03 艾吉纳斯公司 anti-PD-1 antibodies and methods of use thereof
AR106184A1 (en) 2015-09-29 2017-12-20 Celgene Corp PD-1 BINDING PROTEINS AND THEIR METHODS OF USE
LT3370768T (en) 2015-11-03 2022-05-25 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
AU2017246794A1 (en) 2016-04-04 2018-10-25 Genzyme Corporation Anti-complement factor Bb antibodies and uses thereof
TWI822521B (en) 2016-05-13 2023-11-11 美商再生元醫藥公司 Methods of treating skin cancer by administering a pd-1 inhibitor
KR20230149857A (en) 2016-07-07 2023-10-27 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 Antibody adjuvant conjugates
SG11201901950TA (en) 2016-09-19 2019-04-29 Celgene Corp Methods of treating immune disorders using pd-1 binding proteins
EP3515943A4 (en) 2016-09-19 2020-05-06 Celgene Corporation Methods of treating vitiligo using pd-1 binding proteins
CA3042276A1 (en) 2016-12-09 2018-06-14 Seattle Genetics, Inc. Bivalent antibodies masked by coiled coils
CN106519034B (en) 2016-12-22 2020-09-18 鲁南制药集团股份有限公司 anti-PD-1 antibodies and uses thereof
CN109983031B (en) 2016-12-26 2022-11-25 Jcr制药股份有限公司 Novel anti-human transferrin receptor antibodies across the blood brain barrier
CN108341871A (en) * 2017-01-24 2018-07-31 三生国健药业（上海）股份有限公司 Anti- PD-1 monoclonal antibodies and its preparation method and application
WO2018156785A1 (en) * 2017-02-22 2018-08-30 Sutro Biopharma, Inc. Pd-1/tim-3 bi-specific antibodies, compositions thereof, and methods of making and using the same
AU2018224094A1 (en) 2017-02-24 2019-09-19 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
KR102619015B1 (en) 2017-03-15 2023-12-28 큐 바이오파마, 인크. How to Regulate Your Immune Response
JP7257967B2 (en) * 2017-05-01 2023-04-14 ザ チルドレンズ メディカル センター コーポレーション Methods and compositions relating to anti-PD1 antibody reagents
CN110050000B (en) * 2017-05-12 2022-07-26 苏州盛迪亚生物医药有限公司 Fusion protein containing TGF-beta receptor and medical application thereof
JP2020530554A (en) * 2017-07-20 2020-10-22 シートムエックス セラピューティクス，インコーポレイテッド Methods and Uses for Qualitative and / or Quantitative Analysis of Activating Antibody Properties
WO2019036433A2 (en) 2017-08-16 2019-02-21 Bristol-Myers Squibb Company Prodruggable antibodies, prodrugs thereof, and methods of use and making
CN111511762A (en) 2017-08-21 2020-08-07 天演药业公司 anti-CD137 molecules and uses thereof
CN111670051A (en) 2017-11-08 2020-09-15 亚飞（上海）生物医药科技有限公司 Biomolecular conjugates and uses thereof
CN109971714B (en) * 2017-12-28 2023-06-20 上海细胞治疗研究院 Chimeric antigen receptor modified T cells from PD-1 antibody expression and targeting mesothelin and uses thereof
JP2021509896A (en) * 2018-01-08 2021-04-08 ナンジン レジェンド バイオテック カンパニー，リミテッドＮａｎｊｉｎｇ Ｌｅｇｅｎｄ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． Multispecific antigen-binding protein and how to use it
WO2019148410A1 (en) * 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1 antibodies
WO2019148412A1 (en) * 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
WO2019148444A1 (en) * 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
IL276675B2 (en) 2018-02-23 2023-10-01 Eucure Beijing Biopharma Co Ltd Anti-pd-1 antibodies and uses thereof
US11327078B2 (en) * 2018-02-27 2022-05-10 Eisai R&D Management Co., Ltd. Monoclonal antibody against APOA4, immunological measurement method, and kit for measurement
EP3769309A1 (en) 2018-03-20 2021-01-27 Cytomx Therapeutics Inc. Systems and methods for quantitative pharmacological modeling of activatable antibody species in mammalian subjects
WO2019180150A1 (en) * 2018-03-22 2019-09-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for modulating innate lymphoid cell activity, antibody drug conjugates and uses in therapy
SG11202011308VA (en) 2018-05-14 2020-12-30 Werewolf Therapeutics Inc Activatable cytokine polypeptides and methods of use thereof
SG11202011349PA (en) 2018-05-14 2020-12-30 Werewolf Therapeutics Inc Activatable interleukin-2 polypeptides and methods of use thereof
CN110563842B (en) * 2018-06-06 2022-07-29 浙江博锐生物制药有限公司 Antibodies to programmed death ligand (PD-L1) and uses thereof
CN108948202A (en) * 2018-07-25 2018-12-07 博奥信生物技术（南京）有限公司 A kind of anti-human PD1 monoclonal antibody and application thereof
WO2020021061A1 (en) * 2018-07-26 2020-01-30 Pieris Pharmaceuticals Gmbh Humanized anti-pd-1 antibodies and uses thereof
AU2019321271A1 (en) * 2018-08-11 2021-02-11 Guangdong Tcrcure Biopharma Technology Co., Ltd. Dual function engineered T cells with HPV E6 specificity and PD-1 blockade
CN113307872B (en) * 2018-08-11 2022-12-06 广东天科雅生物医药科技有限公司 Engineered nucleic acid, T cell, application and production method thereof
CN110845614A (en) * 2018-08-21 2020-02-28 大有华夏生物医药集团有限公司 Human cell surface immunoregulatory molecules
JP2022512920A (en) * 2018-11-02 2022-02-07 シートムエックス セラピューティクス，インコーポレイテッド Activateable anti-CD166 antibody and how to use it
AU2019382505A1 (en) * 2018-11-19 2021-05-27 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-PD-1 antibodies and uses thereof
TW202039542A (en) 2018-12-19 2020-11-01 美商庫爾生物製藥有限公司 Multimeric t-cell modulatory polypeptides and methods of use thereof
US20220233705A1 (en) * 2019-02-26 2022-07-28 Cytomx Therapeutics, Inc. Combined therapies of activatable immune checkpoint inhibitors and conjugated activatable antibodies
JP2022525594A (en) 2019-03-15 2022-05-18 ボルト バイオセラピューティクス、インコーポレーテッド Immune conjugates targeting HER2
MX2021013766A (en) 2019-05-14 2022-02-21 Werewolf Therapeutics Inc Separation moieties and methods and use thereof.
WO2020246737A1 (en) * 2019-06-04 2020-12-10 사회복지법인 삼성생명공익재단 Composition for treating castration-resistant prostate cancer, comprising quassinoids
WO2020251878A1 (en) 2019-06-11 2020-12-17 Bristol-Myers Squibb Company Anti-ctla4 antibody prodruggable (probody) at a cdr position
EP3983439A1 (en) * 2019-06-13 2022-04-20 CytomX Therapeutics, Inc. Use of an activatable anti-pdl1 antibody and an anti-ctla-4 antibody in a combination therapy for the treatment of cancer
US20220372148A1 (en) 2019-07-05 2022-11-24 Ono Pharmaceutical Co., Ltd. A pharmaceutical composition for treating hematological cancer
EP3997126A4 (en) * 2019-07-09 2024-01-24 Zydus Lifesciences Ltd Antibodies to human programmed death receptor pd-1
WO2021025140A1 (en) 2019-08-08 2021-02-11 小野薬品工業株式会社 Dual-specific protein
WO2021063201A1 (en) * 2019-09-30 2021-04-08 四川科伦博泰生物医药股份有限公司 Anti-pd-1 antibody and use thereof
CN113244385A (en) * 2020-02-07 2021-08-13 上海君实生物医药科技股份有限公司 Use of anti-PD-1 antibodies in the treatment of malignant tumors
EP4132656A1 (en) 2020-04-09 2023-02-15 CytomX Therapeutics, Inc. Compositions containing activatable antibodies
CA3173325A1 (en) * 2020-04-20 2021-10-28 Graham Parry Humanized anti-complement factor bb antibodies and uses thereof
CN115916224A (en) * 2020-04-24 2023-04-04 纪念斯隆-凯特琳癌症中心 Chimeric antigen receptor targeting CD19 and uses thereof
CN113559257A (en) * 2020-04-29 2021-10-29 石药集团中奇制药技术（石家庄）有限公司 Application of PD-1 inhibitor in preparation of medicine for treating specific tumor subtype
WO2022015716A2 (en) * 2020-07-13 2022-01-20 The Children's Medical Center Corporation Novel anti-pd1 antibodies for inhibiting t-cell activity
TW202204418A (en) * 2020-07-16 2022-02-01 大陸商和鉑醫藥（上海）有限責任公司 Pd-1 antigen binding protein and application thereof
JP2023537412A (en) 2020-08-13 2023-08-31 ブリストル－マイヤーズ スクイブ カンパニー Methods of Redirecting IL-2 to Target Cells of Interest
JP2023542490A (en) 2020-09-03 2023-10-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Method of treating cancer pain by administering a PD-1 inhibitor
WO2022171104A1 (en) * 2021-02-10 2022-08-18 上海济煜医药科技有限公司 Anti-pd-1 antibody and use thereof
CN113480648B (en) * 2021-05-13 2022-09-09 华东师范大学 Murine blocking antibody for human CD47 and preparation and application thereof
EP4353746A1 (en) * 2021-06-11 2024-04-17 Guangdong Fapon Biopharma Inc. Anti-pd-1 humanized antibody or antigen-binding fragment thereof and application thereof
WO2023009891A2 (en) * 2021-07-30 2023-02-02 Janssen Biotech, Inc. Materials and methods of making or using il-23r binding proteins
IL286430A (en) * 2021-09-14 2023-04-01 Yeda Res & Dev Multispecific antibodies for use in treating diseases
CA3233707A1 (en) 2021-10-08 2023-04-13 Alexey Yevgenyevich Berezhnoy Activatable cytokine constructs and combination methods
US20230174995A1 (en) 2021-10-15 2023-06-08 Cytomx Therapeutics, Inc. Activatable polypeptide complex
WO2023183758A2 (en) * 2022-03-19 2023-09-28 Regeneron Pharmaceuticals, Inc. Multispecific molecules targeting cd3 and mage-a4 and uses thereof
WO2023183888A1 (en) 2022-03-23 2023-09-28 Cytomx Therapeutics, Inc. Activatable antigen-binding protein constructs and uses of the same
WO2023183923A1 (en) 2022-03-25 2023-09-28 Cytomx Therapeutics, Inc. Activatable dual-anchored masked molecules and methods of use thereof
WO2023192606A2 (en) 2022-04-01 2023-10-05 Cytomx Therapeutics, Inc. Cd3-binding proteins and methods of use thereof
WO2023192973A1 (en) 2022-04-01 2023-10-05 Cytomx Therapeutics, Inc. Activatable multispecific molecules and methods of use thereof
WO2024030843A1 (en) 2022-08-01 2024-02-08 Cytomx Therapeutics, Inc. Protease-cleavable moieties and methods of use thereof
WO2024030847A1 (en) 2022-08-01 2024-02-08 Cytomx Therapeutics, Inc. Protease-cleavable moieties and methods of use thereof
WO2024030850A1 (en) 2022-08-01 2024-02-08 Cytomx Therapeutics, Inc. Protease-cleavable substrates and methods of use thereof
WO2024030845A1 (en) 2022-08-01 2024-02-08 Cytomx Therapeutics, Inc. Protease-cleavable moieties and methods of use thereof
WO2024030858A1 (en) 2022-08-01 2024-02-08 Cytomx Therapeutics, Inc. Protease-cleavable substrates and methods of use thereof

Family Cites Families (315)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
EP0279862B1 (en) 1986-08-28 1993-11-03 Teijin Limited Cytocidal antibody complex and process for its preparation
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
US6936704B1 (en) 1999-08-23 2005-08-30 Dana-Farber Cancer Institute, Inc. Nucleic acids encoding costimulatory molecule B7-4
BR0013581A (en) 1999-08-23 2002-07-02 Dana Faber Cancer Inst Inc Pd-1, a receiver for b7-4, and uses for it
EP1234031B2 (en) 1999-11-30 2021-11-24 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
WO2001091798A2 (en) 2000-06-01 2001-12-06 Universite Catholique De Louvain Tumor activated prodrug compounds
NZ522844A (en) 2000-06-28 2005-02-25 Brigham & Womens Hospital PD-L2 molecules: novel PD-1 ligands and methods to identify compounds to modulate T cell activation
JP4334866B2 (en) 2000-10-09 2009-09-30 アイシス イノヴェイション リミテッド Therapeutic antibody
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
AR036993A1 (en) 2001-04-02 2004-10-20 Wyeth Corp USE OF AGENTS THAT MODULATE THE INTERACTION BETWEEN PD-1 AND ITS LINKS IN THE SUBMODULATION OF IMMUNOLOGICAL ANSWERS
CA2442066C (en) 2001-04-02 2005-11-01 Wyeth Pd-1, a receptor for b7-4, and uses therefor
ATE524495T1 (en) 2001-07-31 2011-09-15 Ono Pharmaceutical Co PD-1 SPECIFIC SUBSTANCE
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
EP3287144A1 (en) * 2002-07-03 2018-02-28 ONO Pharmaceutical Co., Ltd. Immunopotentiating compositions
US20040109855A1 (en) 2002-07-23 2004-06-10 Herman Waldmann Therapeutic antibodies with reduced side effect
US8809504B2 (en) 2002-09-03 2014-08-19 Vit Lauermann Inhibitor which is deactivatable by a reagent produced by a target cell
US7432351B1 (en) 2002-10-04 2008-10-07 Mayo Foundation For Medical Education And Research B7-H1 variants
US7449300B2 (en) 2002-11-21 2008-11-11 Mayo Foundation For Medical Education And Research Detection of antibodies specific for B7-H1 in subjects with diseases or pathological conditions mediated by activated T cells
JP4511943B2 (en) 2002-12-23 2010-07-28 ワイス エルエルシー Antibody against PD-1 and use thereof
EP1591527B1 (en) 2003-01-23 2015-08-26 Ono Pharmaceutical Co., Ltd. Substance specific to human pd-1
PL1810026T3 (en) 2004-10-06 2018-08-31 Mayo Foundation For Medical Education And Research B7-h1 and pd-1 in treatment of renal cell carcinoma
EP2418278A3 (en) 2005-05-09 2012-07-04 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
CA2620886C (en) 2005-08-31 2017-03-14 The Regents Of The University Of California Cellular libraries of peptide sequences (clips) and methods of using the same
JP2009529522A (en) 2006-03-10 2009-08-20 ディアト Anticancer drug conjugated to antibody via enzyme-cleavable linker
AU2007339897B2 (en) 2006-12-27 2013-02-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for the treatment of infections and tumors
EP3222634A1 (en) 2007-06-18 2017-09-27 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
EP2195347A1 (en) 2007-08-17 2010-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating and diagnosing hematologic malignancies
CA2697032C (en) 2007-08-22 2021-09-14 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
PT2242773T (en) 2008-02-11 2017-09-15 Cure Tech Ltd Monoclonal antibodies for tumor treatment
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
RS54233B1 (en) 2008-08-25 2015-12-31 Amplimmune Inc. Compositions of pd-1 antagonists and methods of use
JP2012501670A (en) 2008-09-12 2012-01-26 アイシス・イノベーション・リミテッド PD-1-specific antibodies and uses thereof
JP5794917B2 (en) 2008-09-12 2015-10-14 アイシス・イノベーション・リミテッドＩｓｉｓ Ｉｎｎｏｖａｔｉｏｎｌｉｍｉｔｅｄ PD-1-specific antibodies and uses thereof
CN108484767B (en) 2008-09-26 2022-01-14 达纳-法伯癌症研究公司 Human anti-PD-1, PD-L1 and PD-L2 antibodies and uses thereof
KR101050829B1 (en) 2008-10-02 2011-07-20 서울대학교산학협력단 Anticancer agents comprising an anti-PD-1 antibody or an anti-PD-L1 antibody
US9598491B2 (en) * 2008-11-28 2017-03-21 Emory University Methods for the treatment of infections and tumors
EP2385955B1 (en) 2009-01-12 2020-08-12 CytomX Therapeutics, Inc. Modified antibody compositions, methods of making and using thereof
EP3192811A1 (en) 2009-02-09 2017-07-19 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
CA2761310C (en) 2009-05-07 2017-02-28 Charles S. Craik Antibodies and methods of use thereof
WO2011109789A2 (en) 2010-03-05 2011-09-09 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
WO2011110604A1 (en) 2010-03-11 2011-09-15 Ucb Pharma, S.A. Pd-1 antibody
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
WO2011159877A2 (en) 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
WO2012018538A2 (en) 2010-07-26 2012-02-09 Schering Corporation Bioassays for determining pd-1 modulation
EP2691112B1 (en) 2011-03-31 2018-05-23 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
PL2699264T3 (en) 2011-04-20 2018-08-31 Medimmune, Llc Antibodies and other molecules that bind b7-h1 and pd-1
EP2734551B1 (en) 2011-07-24 2018-01-10 Cure Tech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
ES2708669T3 (en) 2011-08-01 2019-04-10 Hoffmann La Roche Cancer treatment procedures using PD-1 axis-binding antagonists and MEK inhibitors
US9701749B2 (en) * 2011-08-11 2017-07-11 Ono Pharmaceutical Co., Ltd. Therapeutic agent for autoimmune diseases comprising PD-1 agonist
WO2013043569A1 (en) 2011-09-20 2013-03-28 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
US8956619B2 (en) 2011-10-25 2015-02-17 University Of Maryland, Baltimore County Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
US9212224B2 (en) * 2012-05-15 2015-12-15 Bristol-Myers Squibb Company Antibodies that bind PD-L1 and uses thereof
WO2013192546A1 (en) 2012-06-22 2013-12-27 Cytomx Therapeutics, Inc. Activatable antibodies having non-binding steric moieties and mehtods of using the same
US9309510B2 (en) 2012-08-10 2016-04-12 Cytomx Therapeutics, Inc. Protease-resistant systems for polypeptide display and methods of making and using thereof
WO2014028502A1 (en) 2012-08-13 2014-02-20 ImmunGene Inc. Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases
US9382329B2 (en) 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
US10131712B2 (en) 2012-08-14 2018-11-20 Ibc Pharmaceuticals, Inc. Combination therapy with T-cell redirecting bispecific antibodies and checkpoint inhibitors
US9107728B2 (en) 2012-09-23 2015-08-18 Mark Philip Breazzano Eyeball stabilizing apparatus and method of use
US20150273056A1 (en) 2012-10-12 2015-10-01 The Brigham And Women's Hospital, Inc. Enhancement of the immune response
EP2911669B1 (en) 2012-10-26 2024-04-10 The University of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
WO2014074852A1 (en) 2012-11-09 2014-05-15 President And Fellows Of Harvard College Compositions and methods for modulating an immune response
CN116637183A (en) 2012-12-03 2023-08-25 百时美施贵宝公司 Enhancing anti-cancer activity of immunomodulatory Fc fusion proteins
CA2896797A1 (en) 2013-01-11 2014-07-17 Dingfu Biotarget Co., Ltd Agents for treating tumours, use and method thereof
EP2953645A4 (en) 2013-02-07 2016-12-28 Immunomedics Inc Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
JP6605444B2 (en) 2013-03-12 2019-11-13 バイオコン・リミテッド Fusion immunoregulatory protein and production method thereof
EA038981B1 (en) 2013-03-14 2021-11-17 Икан Скул Оф Медсин Эт Маунт Синай Newcastle disease viruses and uses thereof
WO2014161509A1 (en) 2013-04-05 2014-10-09 The University Of Hong Kong Novel pd1 isoforms, and uses thereof for potentiating immune responses
SI2992017T1 (en) 2013-05-02 2021-04-30 Anaptysbio, Inc. Antibodies directed against programmed death-1 (pd-1)
CN103242448B (en) 2013-05-27 2015-01-14 郑州大学 Full-humanized anti-PD-1 monoclonal antibody and preparation method and application thereof
WO2014194293A1 (en) 2013-05-30 2014-12-04 Amplimmune, Inc. Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof
WO2014194302A2 (en) 2013-05-31 2014-12-04 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
EP3003316B1 (en) 2013-05-31 2020-07-22 Merck Sharp & Dohme Corp. Combination therapies for cancer
WO2014197369A1 (en) 2013-06-06 2014-12-11 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment prevention, and treatment of cancer using pd-l1 isoforms
WO2014209804A1 (en) 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
KR20150001215A (en) 2013-06-26 2015-01-06 삼성전자주식회사 Apparatus and method of photographing breast image using x-ray
CN104250302B (en) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 The anti-antibody of PD 1 and its application
FR3008408B1 (en) 2013-07-11 2018-03-09 Mc Saf NOVEL ANTIBODY-MEDICAMENT CONJUGATES AND THEIR USE IN THERAPY
RU2705795C2 (en) 2013-08-20 2019-11-12 Мерк Шарп И Доум Корп. Treating cancer with combination of pd-1 antagonist and dinaciclib
AR097306A1 (en) 2013-08-20 2016-03-02 Merck Sharp & Dohme MODULATION OF TUMOR IMMUNITY
WO2015035112A1 (en) 2013-09-05 2015-03-12 The Johns Hopkins University Cancer therapy via a combination of epigenetic modulation and immune modulation
WO2015038538A1 (en) 2013-09-10 2015-03-19 Medimmune, Llc Compositions and methods for treating sepsis
WO2015036394A1 (en) 2013-09-10 2015-03-19 Medimmune Limited Antibodies against pd-1 and uses thereof
CN108715615B (en) 2013-09-13 2020-11-27 百济神州(广州)生物科技有限公司 anti-PD 1 antibodies and their use as therapeutic and diagnostic agents
SG11201601763SA (en) 2013-09-20 2016-04-28 Bristol Myers Squibb Co Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
ES2714708T3 (en) 2013-10-01 2019-05-29 Mayo Found Medical Education & Res Procedures for the treatment of cancer in patients with elevated levels of Bim
US20160215061A1 (en) 2013-10-08 2016-07-28 Merck Sharp & Dohme Corp. Fc CONTAINING POLYPEPTIDES HAVING INCREASED BINDING TO FcGammaRIIB
US20150118222A1 (en) 2013-10-25 2015-04-30 Pharmacyclics, Inc. Treatment using bruton's tyrosine kinase inhibitors and immunotherapy
CN104558177B (en) 2013-10-25 2020-02-18 苏州思坦维生物技术股份有限公司 Monoclonal antibody for antagonizing and inhibiting programmed death receptor PD-1and ligand combination thereof, and coding sequence and application thereof
CN104560884A (en) 2013-10-25 2015-04-29 苏州思坦维生物技术有限责任公司 Monoclonal antibodies for antagonizing and inhibiting combination of programmed death-1 (PD-1) and ligands of PD-1, hybridoma cell line secreting monoclonal antibodies and application of monoclonal antibodies
WO2015069697A2 (en) 2013-11-05 2015-05-14 Nkt Therapeutics Inc. Combination therapy
DK3065770T3 (en) 2013-11-05 2021-01-11 Bavarian Nordic As COMBINATION THERAPY FOR THE TREATMENT OF CANCER WITH A POX VIRUS EXPRESSING A TUMOR ANTIGEN AND AN ANTAGONIST OF AN IMMUNCH CHECKPOINT INHIBITOR
CN105828834A (en) 2013-11-05 2016-08-03 同源生物服务股份有限公司 Combinations of checkpoint inhibitors and therapeutics to treat cancer
AU2014351308B2 (en) 2013-11-25 2020-03-05 Ccam Biotherapeutics Ltd. Compositions comprising anti-CEACAM1 and anti-PD antibodies for cancer therapy
WO2015088930A1 (en) 2013-12-10 2015-06-18 Merck Sharp & Dohme Corp. Immunohistochemical proximity assay for pd-1 positive cells and pd-ligand positive cells in tumor tissue
EP3079699A4 (en) 2013-12-11 2017-07-19 Glaxosmithkline LLC Treating cancer with a combination of a pd-1 antagonist and a vegfr inhibitor
CN104711292A (en) 2013-12-11 2015-06-17 深圳先进技术研究院 Method for developing membrane expression PD-1 stable transfected cells
MY184154A (en) 2013-12-12 2021-03-23 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
EP3084003A4 (en) 2013-12-17 2017-07-19 Merck Sharp & Dohme Corp. Ifn-gamma gene signature biomarkers of tumor response to pd-1 antagonists
US20150190506A1 (en) 2013-12-17 2015-07-09 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
US20160312295A1 (en) 2013-12-17 2016-10-27 Merck Sharp & Dohme Corp. Gene signature biomarkers of tumor response to pd-1 antagonists
SG11201604875PA (en) 2013-12-17 2016-07-28 Genentech Inc Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
SG11201604995YA (en) 2013-12-17 2016-07-28 Genentech Inc Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies
PE20161217A1 (en) 2013-12-17 2016-11-16 Genentech Inc ANTI-CD3 ANTIBODIES AND METHODS OF USE
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US20160312297A1 (en) 2013-12-17 2016-10-27 Merck Sharp & Dohme Corp. Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonists
WO2015092393A2 (en) 2013-12-17 2015-06-25 Kymab Limited Human targets
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
CN105980402B (en) 2013-12-20 2021-06-15 弗雷德哈钦森癌症研究中心 Tagged chimeric effector molecules and receptors thereof
CN117603354A (en) 2013-12-20 2024-02-27 英特维特国际股份有限公司 Canine antibodies with modified CH2-CH3 sequences
BR112016014410A2 (en) 2013-12-20 2018-02-20 The Broad Institute Inc. neoantigen vaccine combination therapy
WO2015103072A1 (en) 2013-12-30 2015-07-09 Epimab Biotherapeutics Fabs-in-tandem immunoglobulin and uses thereof
WO2015103602A1 (en) 2014-01-06 2015-07-09 The Trustees Of The University Of Pennsylvania Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
CN103721255A (en) 2014-01-07 2014-04-16 苏州大学 Application of co-blocking of PD-1 and TIM-3 signal paths to anti-stomach-cancer treatment
EP3094650A2 (en) 2014-01-13 2016-11-23 Pieris Pharmaceuticals GmbH Multi-specific polypeptide useful for localized tumor immunomodulation
WO2015112534A2 (en) 2014-01-21 2015-07-30 Medimmune, Llc Compositions and methods for modulating and redirecting immune responses
TWI681969B (en) 2014-01-23 2020-01-11 美商再生元醫藥公司 Human antibodies to pd-1
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody molecules to pd-1 and uses thereof
CN106456753B (en) 2014-02-04 2021-05-11 因塞特公司 Combination of a PD-1 antagonist and an IDO1 inhibitor for the treatment of cancer
TW201613635A (en) 2014-02-04 2016-04-16 Pfizer Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
EP3572430A3 (en) 2014-03-05 2020-02-12 Bristol-Myers Squibb Company Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
CA2944456C (en) 2014-03-31 2023-10-31 The Johns Hopkins University Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-ctla-4 and/or anti-pd-1 antibodies to treat solid tumor malignancies
US20170165230A1 (en) 2014-04-09 2017-06-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
EP3137105A4 (en) 2014-04-30 2017-12-27 President and Fellows of Harvard College Combination vaccine devices and methods of killing cancer cells
KR102499737B1 (en) 2014-05-13 2023-02-13 버베리안 노딕 에이/에스 Combination therapy for treating cancer with a recombinant poxvirus expressing a tumor antigen and an immune checkpoint molecule antagonist or agonist
AU2015260230A1 (en) 2014-05-13 2016-11-17 Chugai Seiyaku Kabushiki Kaisha T cell-redirected antigen-binding molecule for cells having immunosuppression function
CN115590953A (en) 2014-05-15 2023-01-13 百时美施贵宝公司（Us） Treatment of lung cancer using a combination of an anti-PD-1 antibody and another anti-cancer agent
CN105085680A (en) 2014-05-23 2015-11-25 复旦大学 Humanized anti-PD-1 and c-MET bispecific antibody, and preparation method and application thereof
JP2017517525A (en) 2014-05-29 2017-06-29 メディミューン リミテッド PDL-1 and PD-1 antagonists for the treatment of HPV negative cancer
EP3683238A1 (en) 2014-06-19 2020-07-22 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized programmed cell death 1 gene
WO2015195163A1 (en) 2014-06-20 2015-12-23 R-Pharm Overseas, Inc. Pd-l1 antagonist fully human antibody
WO2015200828A1 (en) 2014-06-27 2015-12-30 H. Lee Moffit Cancer Center And Research Institute, Inc. Conjugates for immunotherapy
EP3166975A1 (en) 2014-07-07 2017-05-17 Dana-Farber Cancer Institute, Inc. Methods of treating cancer
CN112546231A (en) 2014-07-09 2021-03-26 博笛生物科技有限公司 Combination therapeutic compositions and combination therapeutic methods for treating cancer
JP6760919B2 (en) 2014-07-09 2020-09-23 バーディー バイオファーマシューティカルズ インコーポレイテッド Anti-PD-L1 combination for treating tumors
JP6279733B2 (en) 2014-07-09 2018-02-14 日本全薬工業株式会社 Anti-canine PD-1 antibody or anti-canine PD-L1 antibody
EP3169361B1 (en) 2014-07-15 2019-06-19 F.Hoffmann-La Roche Ag Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
PT3169341T (en) 2014-07-16 2019-09-09 Transgene Sa Oncolytic virus for expression of immune checkpoint modulators
CA2955084C (en) 2014-07-16 2023-08-29 Transgene Sa Combination of oncolytic virus with immune checkpoint modulators
CN106999561A (en) 2014-07-18 2017-08-01 阿德瓦希斯股份有限公司 Combination for treating the antagonists of PD 1 of prostate cancer and vaccine based on Listeria
NZ728688A (en) 2014-07-22 2023-06-30 Cb Therapeutics Inc Anti-pd-1 antibodies
WO2016014799A1 (en) 2014-07-23 2016-01-28 University Of Iowa Research Foundation Epidermal growth factor and blockade of immune checkpoints in cancer immunotherapy
CA2955947A1 (en) * 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
CN105330740B (en) 2014-07-30 2018-08-17 珠海市丽珠单抗生物技术有限公司 Anti- PD-1 antibody and its application
US9982052B2 (en) 2014-08-05 2018-05-29 MabQuest, SA Immunological reagents
PL3177644T3 (en) 2014-08-05 2021-06-14 MabQuest SA Immunological reagents binding to pd-1
DK3177640T3 (en) 2014-08-08 2020-08-10 Univ Leland Stanford Junior HIGH AFFINITY PD-1 AGENTS AND USE PROCEDURES
WO2016029073A2 (en) 2014-08-22 2016-02-25 Bristol-Myers Squibb Company Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
WO2016032927A1 (en) 2014-08-25 2016-03-03 Pfizer Inc. Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
EP3191104A1 (en) 2014-09-08 2017-07-19 Celgene Corporation Methods for treating a disease or disorder using oral formulations of cytidine analogs in combination with an anti-pd1 or anti-pdl1 monoclonal antibody
KR20170072244A (en) 2014-10-10 2017-06-26 이데라 파마슈티칼즈, 인코포레이티드 Treatment of cancer using tlr9 agonist with checkpoint inhibitors
WO2016059602A2 (en) 2014-10-16 2016-04-21 Glaxo Group Limited Methods of treating cancer and related compositions
JP2017533207A (en) 2014-10-23 2017-11-09 ファイヴ プライム セラピューティクス インク SLAMF1 antagonist and use thereof
EP3550019A1 (en) 2014-10-24 2019-10-09 Astrazeneca AB Combination
EP3212670B1 (en) 2014-10-29 2020-12-23 Five Prime Therapeutics, Inc. Combination therapy for cancer
EP3212233B1 (en) 2014-10-31 2020-06-24 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
CN105622753B (en) 2014-11-04 2019-04-09 博生吉医药科技(苏州)有限公司 A kind of PD-1 monoclonal antibody and its application
WO2016071701A1 (en) 2014-11-07 2016-05-12 Kymab Limited Treatment of disease using ligand binding to targets of interest
US20190076452A1 (en) 2014-11-11 2019-03-14 Medimmune Limited Therapeutic combinations for treating neoplasia
EP3218409A2 (en) 2014-11-11 2017-09-20 Sutro Biopharma, Inc. Anti-pd-1 antibodies, compositions comprising anti-pd-1 antibodies and methods of using anti-pd-1 antibodies
KR20170096112A (en) 2014-11-17 2017-08-23 제넨테크, 인크. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
EA201791049A1 (en) 2014-12-04 2017-10-31 Бристол-Майерс Сквибб Компани COMBINATION ANTI-CS1 AND ANTI-PD1 ANTIBODIES FOR CANCER TREATMENT (MYELOMA)
TWI595006B (en) 2014-12-09 2017-08-11 禮納特神經系統科學公司 Anti-pd-1 antibodies and methods of use thereof
US10239942B2 (en) 2014-12-22 2019-03-26 Pd-1 Acquisition Group, Llc Anti-PD-1 antibodies
US10849862B2 (en) 2014-12-26 2020-12-01 Theravalues Corporation Formulation of curcumin and anti-PD-1 antibody
CN104479020B (en) 2014-12-26 2019-08-02 上海复宏汉霖生物技术股份有限公司 A kind of anti-PD-1 human antibody
US10682365B2 (en) 2014-12-31 2020-06-16 Checkmate Pharmaceuticals, Inc. Combination tumor immunotherapy
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
BR112017015136A2 (en) 2015-01-14 2018-01-30 Compass Therapeutics Llc multispecific immunomodulator antigen binding construct polypeptide, multispecific immunomodulator antigen binding construct, conjugate, pharmaceutical composition, method for treating an individual with cancer, method for inhibiting or reducing cancer growth, composition, cell, method of making a polypeptide of multispecific immunomodulatory antigen binding construct, vector or vector set and kit
TWI610940B (en) 2015-01-16 2018-01-11 中央研究院 Molecular constructs for treating tumors
EP3250229B1 (en) 2015-01-29 2022-07-27 The Trustees of the University of Pennsylvania Checkpoint inhibitor and vaccine combinations and use of same for immunotherapy
MA41460A (en) 2015-02-03 2017-12-12 Oncomed Pharm Inc TNFRSF LIAISON AGENTS AND THEIR USES
WO2016128912A1 (en) 2015-02-12 2016-08-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor, and/or a pd-l1 inhibitor
AR103726A1 (en) 2015-02-27 2017-05-31 Merck Sharp & Dohme HUMAN ANTI-PD-1 MONOCLONAL ANTIBODY CRYSTALS
RU2737216C2 (en) 2015-03-04 2020-11-26 Мерк Шарп Энд Дохме Корп. Combination of pd-1 antagonist and eribulin for treating cancer
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
WO2016144673A1 (en) 2015-03-06 2016-09-15 Dana-Farber Cancer Institute, Inc. Pd-l2 biomarkers predictive of pd-1 pathway inhibitor responses in esophagogastric cancers
EP3067062A1 (en) 2015-03-13 2016-09-14 Ipsen Pharma S.A.S. Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament
MA42971A (en) * 2015-03-13 2018-08-15 Cytomx Therapeutics Inc ANTI-PDL1 ANTIBODIES, ACTIVABLE ANTI-PLD1 ANTIBODIES, AND METHODS OF USE THEREOF
US20180044418A1 (en) 2015-03-20 2018-02-15 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and vorinostat for treating cancer
WO2016154412A2 (en) 2015-03-26 2016-09-29 The Trustees Of The University Of Pennsylvania Combination of a pd-1 antagonist and a listeria based vaccine for treating pancreatic cancer
US20180071340A1 (en) 2015-03-30 2018-03-15 Dana-Farber Cancer Institute, Inc. Compositions and methods of treating multiple myeloma
US20180085398A1 (en) 2015-03-30 2018-03-29 Dana-Farber Cancer Institute, Inc. Compositions and methods of treating cancer
AU2016243629B2 (en) 2015-03-30 2021-02-18 Beth Israel Deaconess Medical Center Compositions and methods of treating cancer
US20180078626A1 (en) 2015-03-30 2018-03-22 Dana-Farber Cancer Institute, Inc. Compositions and methods of treating renal cell cancer
EP3277291A1 (en) 2015-03-30 2018-02-07 Dana Farber Cancer Institute, Inc. Compositions and methods of treating acute myeloid leukemia
CN108136001B (en) 2015-04-03 2022-07-29 佐马技术有限公司 Treatment of cancer using TGF-beta inhibitors and PD-1 inhibitors
US20180088111A1 (en) 2015-04-14 2018-03-29 Bristol-Myers Squibb Company IMMUNOASSAY FOR SOLUBLE PROGRAMMED DEATH-1 (sPD-1) PROTEIN
EP3839510A3 (en) 2015-04-17 2021-08-25 Merck Sharp & Dohme Corp. Blood-based biomarkers of tumor sensitivity to pd-1 antagonists
PT3283107T (en) 2015-04-17 2020-08-31 Bristol Myers Squibb Co Compositions comprising a combination of an anti-pd-1 antibody and another antibody
WO2016172249A1 (en) 2015-04-20 2016-10-27 Etubics Corporation Methods and compositions for combination immunotherapy
WO2016170039A1 (en) 2015-04-23 2016-10-27 F. Hoffmann-La Roche Ag Combination therapy of antibody binding to angiopoietin 2 with antibody binding to programmed death 1 polypeptide
EP3288980B1 (en) 2015-04-28 2021-03-10 Bristol-Myers Squibb Company Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody
EP3988571A1 (en) 2015-04-28 2022-04-27 Bristol-Myers Squibb Company Treatment of pd-l1-negative melanoma using an anti-pd-1 antibody and an anti-ctla-4 antibody
WO2016175275A1 (en) 2015-04-30 2016-11-03 国立大学法人京都大学 Method for predicting therapeutic effect of pd-1/pd-l1 inhibitor using abnormality in pd-l1(cd274) as index
WO2016183469A1 (en) 2015-05-13 2016-11-17 Robert Kirken Anti-ctla-4 blockade
CA2929848A1 (en) 2015-05-14 2016-11-14 Pfizer Inc. Combination therapies comprising a pyrrolidine-2,5-dione ido1 inhibitor and an anti-pd1/anti-pd-l1 antibody
WO2016191751A1 (en) 2015-05-28 2016-12-01 Bristol-Myers Squibb Company Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
US20160347836A1 (en) 2015-05-28 2016-12-01 Bristol-Myers Squibb Company Treatment of hodgkin's lymphoma using an anti-pd-1 antibody
CN105061597B (en) 2015-06-09 2016-04-27 北京东方百泰生物科技有限公司 The monoclonal antibody of a kind of anti-PD-1 and preparation method thereof
WO2016205320A1 (en) 2015-06-17 2016-12-22 Genentech, Inc. Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
KR20180019725A (en) 2015-06-23 2018-02-26 메모리얼 슬로안-케터링 캔서 센터 Novel pd-1 immune modulating agents
AU2016286091B2 (en) 2015-06-29 2021-02-04 Verastem, Inc. Therapeutic compositions, combinations, and methods of use
MY189159A (en) 2015-07-06 2022-01-29 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
WO2017007985A1 (en) 2015-07-09 2017-01-12 Bristol-Myers Squibb Company Treatment of cancer using a combination of an anti-pd-1 antibody and il-6
KR20180027576A (en) 2015-07-14 2018-03-14 브리스톨-마이어스 스큅 컴퍼니 How to treat cancer using immune checkpoint inhibitors
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
CN106336460B (en) 2015-07-15 2021-02-12 杭州贝颐药业有限公司 Anti-human PD-1 protein antibody and coding gene and application thereof
US20170021019A1 (en) 2015-07-22 2017-01-26 Matthew Zibelman COMBINATION OF IMMUNOMODULATORY AGENT WITH PD-1 or PD-L1 CHECKPOINT INHIBITORS IN THE TREATMENT OF CANCER
CN106699888B (en) 2015-07-28 2020-11-06 上海昀怡健康科技发展有限公司 PD-1 antibody and preparation method and application thereof
CA2991857A1 (en) 2015-07-29 2017-02-02 Novartis Ag Novel combination for use in the treatment of cancer
WO2017017624A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination of pd-1 antagonist with an egfr inhibitor
JP6878405B2 (en) 2015-07-29 2021-05-26 ノバルティス アーゲー Combination therapy with antibody molecule against PD-1
JO3736B1 (en) 2015-07-30 2021-01-31 Macrogenics Inc PD-1-Binding Molecules and Methods of Use Thereof
WO2017020291A1 (en) 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
EP3331901A1 (en) 2015-08-07 2018-06-13 Pieris Pharmaceuticals GmbH Novel fusion polypeptide specific for lag-3 and pd-1
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
IL293385A (en) 2015-08-11 2022-07-01 Omniab Inc Novel anti-pd-1 antibodies
CN106432494B9 (en) 2015-08-11 2022-02-15 广州誉衡生物科技有限公司 Novel anti-PD-1 antibodies
WO2017024515A1 (en) 2015-08-11 2017-02-16 Wuxi Biologics (Cayman) Inc. Novel anti-pd-1 antibodies
CN107949573B (en) 2015-09-01 2022-05-03 艾吉纳斯公司 anti-PD-1 antibodies and methods of use thereof
WO2017040960A1 (en) 2015-09-04 2017-03-09 The Brigham And Women's Hospital, Inc. Programmed cell death 1 (pd-1 ) inhibitor therapy for patients with pd-1 -expressing cancers
US9995753B2 (en) 2015-09-25 2018-06-12 Merck Sharp & Dohme Corp. Anti-pembrolizumab antibodies
AU2016329960A1 (en) 2015-09-28 2018-04-26 Jiangsu Hengrui Medicine Co., Ltd. Stable anti-PD-1 antibody pharmaceutical preparation and application thereof in medicine
CA3000638C (en) 2015-09-29 2024-02-27 Asia Biotech Pte. Ltd. Pd-1 antibodies and uses thereof
AR106184A1 (en) 2015-09-29 2017-12-20 Celgene Corp PD-1 BINDING PROTEINS AND THEIR METHODS OF USE
US11639389B2 (en) 2015-09-30 2023-05-02 Igm Biosciences, Inc. Binding molecules with modified J-chain
WO2017055404A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific antibodies specific for pd1 and tim3
HRP20221041T1 (en) 2015-10-02 2022-11-11 Symphogen A/S Anti-pd-1 antibodies and compositions
JP6654694B2 (en) 2015-10-02 2020-02-26 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Anti-PD1 antibody and method of use
US20180296561A1 (en) 2015-10-07 2018-10-18 The University Of North Carolina At Chapel Hill The Methods For Treatment Of Tumors
US10744170B2 (en) 2015-10-15 2020-08-18 Duke University Combination treatment
US11207393B2 (en) 2015-10-16 2021-12-28 President And Fellows Of Harvard College Regulatory T cell PD-1 modulation for regulating T cell effector immune responses
WO2017070135A1 (en) 2015-10-20 2017-04-27 Bristol-Myers Squibb Company Prodrugs of 2-(4-(3-((4-amino-7-cyano-imidazo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)piperaz in-1-yl)propanamide derivatives as ck2 inhibitors for the treatment of cancer
WO2017070137A1 (en) 2015-10-20 2017-04-27 Bristol-Myers Squibb Company Combination of ck2 inhibitors and immune checkpoint modulators for cancer treatment
CN105194668B (en) 2015-10-22 2019-03-26 中国科学院微生物研究所 A kind of preparation method and applications of the conjugate of gp96 albumen and PD1 antibody
CN106632674B (en) 2015-10-30 2018-11-16 泽达生物医药有限公司 A kind of anti-PD-1 monoclonal antibody, its medical composition and its use
WO2017079080A1 (en) 2015-11-02 2017-05-11 The Johns Hopkins University Method of preventing organ transplant rejections using agonists to the pd-1 checkpoint pathway
WO2017079303A1 (en) 2015-11-02 2017-05-11 The Cleveland Clinic Foundation Sequentially orchestrated immune checkpoint therapy for the treatment and prevention of cancer
LT3370768T (en) 2015-11-03 2022-05-25 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
KR102220275B1 (en) 2015-11-18 2021-02-26 머크 샤프 앤드 돔 코포레이션 Pd1 and/or lag3 binders
CN106699889A (en) 2015-11-18 2017-05-24 礼进生物医药科技（上海）有限公司 PD-1 resisting antibody and treatment application thereof
CA3003777A1 (en) 2015-11-18 2017-05-26 Merck Sharp & Dohme Corp. Pd1/ctla4 binders
US11072657B2 (en) 2015-11-18 2021-07-27 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-PD-1 antibody and an anti-CTLA-4 antibody
CN105566496B (en) 2015-11-26 2019-04-02 大庆东竺明生物技术有限公司 The monoclonal antibody and its encoding gene of blocking people's programmed death factor 1 (PD-1) function and application
WO2017096026A1 (en) 2015-12-02 2017-06-08 Stcube, Inc. Antibodies specific to glycosylated pd-1 and methods of use thereof
MX2018007089A (en) 2015-12-14 2019-01-30 Macrogenics Inc Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof.
US10392442B2 (en) 2015-12-17 2019-08-27 Bristol-Myers Squibb Company Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
AU2016369537B2 (en) 2015-12-17 2024-03-14 Novartis Ag Antibody molecules to PD-1 and uses thereof
CN105669864B (en) 2015-12-23 2018-10-16 杭州尚健生物技术有限公司 Anti-human 1 antibody of programmed death receptor and its preparation method and application
CN106928361A (en) 2015-12-31 2017-07-07 上海抗体药物国家工程研究中心有限公司 A kind of monoclonal antibody of anti-human PD-1 and its preparation method and application
EP3400442A4 (en) 2016-01-08 2019-06-26 Biothera, Inc. Beta-glucan immunotherapies affecting the immune microenvironment
JP7089474B2 (en) 2016-01-22 2022-06-22 マブクエスト エスエー Immunological reagents
KR20180101584A (en) 2016-01-27 2018-09-12 브리스톨-마이어스 스큅 컴퍼니 Treatment of lung cancer using a combination of anti-PD-1 antibody and another anticancer agent
WO2017132827A1 (en) 2016-02-02 2017-08-10 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
CU24613B1 (en) 2016-02-06 2022-07-08 Epimab Biotherapeutics Inc FABS TANDEM IMMUNOGLOBULIN BINDING PROTEINS (FIT-IG) BSPECIFIC BINDING TO CMET AND EGFR
CN109312347A (en) 2016-02-19 2019-02-05 希望之城 Bispecific aptamer
WO2017161154A2 (en) 2016-03-16 2017-09-21 H. Lee Moffitt Cancer Center & Research Institute, Inc. Pd1 and pdl-1 expression during progression from myelodysplastic syndrome to acute myelogenous leukemia
CN107286242B (en) 2016-04-01 2019-03-22 中山康方生物医药有限公司 The monoclonal antibody of anti-PD-1
US10568870B2 (en) 2016-04-07 2020-02-25 Chemocentryx, Inc. Reducing tumor burden by administering CCR1 antagonists in combination with PD-1 inhibitors or PD-L1 inhibitors
WO2017177179A1 (en) 2016-04-08 2017-10-12 Gilead Sciences, Inc. Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
RU2018142711A (en) 2016-05-04 2020-06-04 Х. Ли Моффитт Кэнсер Сентер Энд Рисёч Инститьют, Инк. MEANS FOR TARGETING INFLUENCE ON DELTA-OPIOID RECEPTOR FOR MOLECULAR VISUALIZATION AND IMMUNOTHERAPY OF CANCER
EP3452107A4 (en) 2016-05-05 2020-04-15 The Trustees of The University of Pennsylvania Dna monoclonal antibodies targeting checkpoint molecules
AR108377A1 (en) 2016-05-06 2018-08-15 Medimmune Llc BISPECIFIC UNION PROTEINS AND ITS USES
EP3243832A1 (en) 2016-05-13 2017-11-15 F. Hoffmann-La Roche AG Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
TWI822521B (en) 2016-05-13 2023-11-11 美商再生元醫藥公司 Methods of treating skin cancer by administering a pd-1 inhibitor
AU2017266298B2 (en) 2016-05-18 2024-01-04 Boehringer Ingelheim International Gmbh Anti PD-1 and anti-LAG3 antibodies for cancer treatment
WO2017200969A1 (en) 2016-05-20 2017-11-23 Eli Lilly And Company Combination therapy with notch and pd-1 or pd-l1 inhibitors
EA201892587A1 (en) 2016-05-20 2019-04-30 Биохэйвен Фармасьютикал Холдинг Компани Лтд. USE OF GLUTAMAT-MODULATING AGENTS TOGETHER WITH IMMUNOTHERAPY FOR CANCER TREATMENT
EP3463453A1 (en) 2016-05-23 2019-04-10 Eli Lilly and Company Combination of pembrolizumab and abemaciclib for the treatment of cancer
CA3025391A1 (en) 2016-05-26 2017-11-30 Merck Patent Gmbh Pd-1 / pd-l1 inhibitors for cancer treatment
WO2017205801A1 (en) 2016-05-27 2017-11-30 Takeda Pharmaceutical Company Limited Combination of immunotherapy agents and spleen tyrosine kinase inhibitors
FR3051794A1 (en) 2016-05-31 2017-12-01 Lab Francais Du Fractionnement ANTIBODIES FOR THE TREATMENT OF CANCERS
WO2017210058A1 (en) 2016-06-01 2017-12-07 Ibc Pharmaceuticals, Inc. Combination therapy with t-cell redirecting bispecific antibodies and checkpoint inhibitors
PL3463457T3 (en) 2016-06-02 2023-08-21 Bristol-Myers Squibb Company Pd-1 blockade with nivolumab in refractory hodgkin's lymphoma
JP2019517505A (en) 2016-06-02 2019-06-24 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Use of anti-PD-1 antibody in combination with anti-CD30 antibody in lymphoma treatment
KR20230047498A (en) 2016-06-03 2023-04-07 브리스톨-마이어스 스큅 컴퍼니 Use of anti-pd-1 antibody in the treatment of patients with colorectal cancer
JP2019517498A (en) 2016-06-03 2019-06-24 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Anti-PD-1 antibody for use in a method of treating recurrent small cell lung cancer
WO2017210624A1 (en) 2016-06-03 2017-12-07 Bristol-Myers Squibb Company Anti-pd-1 antibody for use in a method of treating a tumor
JP2019517539A (en) 2016-06-07 2019-06-24 マクロジェニクス，インコーポレーテッド Combination therapy
WO2017214182A1 (en) 2016-06-07 2017-12-14 The United States Of America. As Represented By The Secretary, Department Of Health & Human Services Fully human antibody targeting pdi for cancer immunotherapy
KR20230054508A (en) 2016-06-14 2023-04-24 젠코어 인코포레이티드 Bispecific checkpoint inhibitor antibodies
US10669338B2 (en) 2016-06-17 2020-06-02 Immunomedics, Inc. Anti-PD-1 checkpoint inhibitor antibodies that block binding of PD-L1 to PD-1
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
CN106967172B (en) 2016-08-23 2019-01-08 康方药业有限公司 The anti-PD-1 bifunctional antibody of anti-CTLA 4-, its medical composition and its use
CN106977602B (en) 2016-08-23 2018-09-25 中山康方生物医药有限公司 A kind of anti-PD1 monoclonal antibodies, its medical composition and its use
US20190218294A1 (en) 2016-09-09 2019-07-18 Bristol-Myers Squibb Company Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment
CA3035932A1 (en) 2016-09-14 2018-03-22 Abbvie Biotherapeutics Inc. Anti-pd-1 antibodies and their uses
EP3515943A4 (en) 2016-09-19 2020-05-06 Celgene Corporation Methods of treating vitiligo using pd-1 binding proteins
CN114456269A (en) 2016-09-21 2022-05-10 基石药业（苏州）有限公司 Novel PD-1 monoclonal antibody
EP3666794A1 (en) 2016-11-01 2020-06-17 AnaptysBio, Inc. Antibodies directed against programmed death- 1 (pd-1)
WO2018087143A2 (en) 2016-11-08 2018-05-17 Actigen Ltd Anti-pd-1 antibodies
TW201825119A (en) 2016-11-30 2018-07-16 日商協和醱酵麒麟有限公司 Method of treating cancer using anti-ccr4 antibody and anti-pd-1 antibody
CN110300599A (en) 2016-12-07 2019-10-01 艾吉纳斯公司 Antibody and its application method
JOP20190133A1 (en) 2016-12-08 2019-06-02 Innovent Biologics Suzhou Co Ltd Anti-tim-3 antibodies for combination with anti-pd-1 antibodies
TW201828993A (en) 2016-12-12 2018-08-16 日商第一三共股份有限公司 Combination of antibody-drug conjugate and immune checkpoint inhibitor
US11814429B2 (en) 2017-01-06 2023-11-14 Crescendo Biologics Limited Single domain antibodies to programmed cell death (PD-1)
EP3569616B1 (en) 2017-01-13 2021-09-29 Taizhou Hanzhong Biopharmaceutics, Inc. Monoclonal antibody against pd-1 and applications thereof
WO2018156649A1 (en) 2017-02-22 2018-08-30 Flagship Pioneering, Inc. Compositions of t cell modulator (tcm) molecules and uses thereof
BR112019017696A2 (en) 2017-02-27 2020-04-07 Bristol Myers Squibb dosing program for a combination of ceritinib and an anti-pd-1 antibody molecule
SG11201907948TA (en) 2017-03-29 2019-09-27 Celgene Corp Formulations comprising pd-1 binding proteins and methods of making thereof
JP2020515600A (en) 2017-03-31 2020-05-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Anti-cancer combination therapy
AU2018243754A1 (en) 2017-03-31 2019-10-17 Bristol-Myers Squibb Company Methods of treating tumor
AU2018248586A1 (en) 2017-04-05 2019-09-05 Boehringer Ingelheim International Gmbh Anticancer combination therapy
US11285207B2 (en) 2017-04-05 2022-03-29 Hoffmann-La Roche Inc. Bispecific antibodies specifically binding to PD1 and LAG3
CN108314734B (en) 2018-01-31 2021-11-05 中国药科大学 anti-PD-1 monoclonal antibody and application thereof

Also Published As

Publication number Publication date
WO2017011580A2 (en) 2017-01-19
CN108368170A (en) 2018-08-03
CN114591433A (en) 2022-06-07
EP3322732A2 (en) 2018-05-23
US20170044259A1 (en) 2017-02-16
MA42447A (en) 2018-05-23
HK1250033A1 (en) 2018-11-23
IL256771B2 (en) 2023-03-01
ZA201800692B (en) 2022-12-21
JP2018529312A (en) 2018-10-11
KR20180040138A (en) 2018-04-19
MX2021006786A (en) 2021-07-15
US10513558B2 (en) 2019-12-24
JP2022064924A (en) 2022-04-26
CA2991976A1 (en) 2017-01-19
AU2016294440A2 (en) 2019-08-08
WO2017011580A3 (en) 2017-03-30
BR112018000768A2 (en) 2018-09-25
IL256771B (en) 2022-11-01
MX2018000621A (en) 2018-05-11
US20210179713A1 (en) 2021-06-17
AU2016294440B2 (en) 2022-10-13
EA201890285A1 (en) 2018-08-31
AU2016294440A1 (en) 2018-02-22
AU2022231735A1 (en) 2022-10-06
IL256771A (en) 2018-03-29
CN108368170B (en) 2022-04-15
JP7014706B2 (en) 2022-02-01

Similar Documents

Publication Publication Date Title
HK1250033A1 (en) Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
HK1250036A1 (en) Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereof
IL282962A (en) Anti-pd-1 antibodies and methods of use thereof
HK1250037A1 (en) Anti-itga3 antibodies, activatable anti-itga3 antibodies, and methods of use thereof
IL254458B (en) Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
HK1250035A1 (en) Anti-cd71 antibodies, activatable anti-cd71 antibodies, and methods of use thereof
IL273937A (en) Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
IL270921A (en) Activatable anti-pdl1 antibodies, and methods of use thereof
HK1258058A1 (en) Anti-tigit antibodies and methods of use
HK1254880A1 (en) Anti-pd-1 antibodies and uses thereof
HK1244492A1 (en) Anti-pd-1 antibodies and methods of use thereof
HK1252858A1 (en) Anti-cll-1 antibodies and methods of use
HK1247568A1 (en) Anti-pvrig antibodies and methods of use
EP3383914A4 (en) Anti-ox40 antibodies and methods of use thereof
EP3377102C0 (en) Anti-pd-1 antibodies and therapeutic uses thereof
HK1258850A1 (en) Anti-tpbg antibodies and methods of use